Premium
Utility of Sonographically Guided Biopsy in Metabolically Suspected Recurrent Lymphoma
Author(s) -
Soudack Michalle,
Shalom Rachel Bar,
Israel Ora,
Ben-Arie Yehudith,
Levy Zofia,
Gaitini Diana
Publication year - 2008
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.7863/jum.2008.27.2.225
Subject(s) - medicine , biopsy , lymphoma , radiology , positron emission tomography , fluorodeoxyglucose , standardized uptake value , nuclear medicine , pathology
Objective The purpose of this study was to determine the diagnostic accuracy of sonographically guided biopsy of [ 18 F]fluorodeoxyglucose (FDG)‐avid foci on positron emission tomography (PET)/computed tomography (CT) in patients with lymphoma. Methods We retrospectively reviewed the medical records of 56 patients with lymphoma (25 male and 31 female; mean age, 48.5 years; range, 22–80 years) who underwent sonographically guided biopsy of hypermetabolic FDG‐avid foci precisely localized by PET/CT. Biopsies were performed up to 3 months after PET/CT. The accuracy of core biopsy was calculated and compared with clinical follow‐up and histopathologic results of open biopsy.Results Sixty‐six sonographically guided biopsies were performed in the 56 patients. Histopathologic results were conclusive in 53 (80%) of 66. No complications occurred during or after the procedure. The overall sensitivity, specificity, positive predictive value, and accuracy for diagnosis of lymphoma were 100%, 95%, 97%, and 98%, respectively. Conclusions Sonographically guided biopsy is a safe and effective means for investigating metabolically active lesions on FDG‐PET/CT in patients with known lymphoma.